Uses of human zven proteins and polynucleotides

Abstract

The present invention provides methods of using Zven1 and Zven2 polypeptides to increase chemokine production. The present invention also provides methods for treating intestinal motility disorders and improving gastrointestinal function with Zven1 and Zven2 polypeptides.

1 . A method of stimulating CXC chemokine release in a mammal in need thereof, comprising:
 selecting a mammal in need of stimulation of release of a CXC chemokine;   administering to the mammal a polypeptide, wherein the polypeptide comprises the amino acid sequence of amino acid residues 20 to 105 of SEQ ID NO:5; and   measuring the release of a CXC chemokine in a biological sample from said mammal following administration of said polypeptide.   
     
     
         2 . A method of stimulating neutrophil infiltration in a mammal in need thereof, comprising:
 selecting a mammal in need of neutrophil infiltration;   administering to the mammal a polypeptide, wherein the polypeptide comprises the amino acid sequence of amino acid residues 20 to 105 of SEQ ID NO:5; and   measuring the infiltration of neutrophils in a biological sample from said mammal following administration of said polypeptide.   
     
     
         3 . A method of stimulating CXC chemokine release in a mammal in need thereof, comprising:
 selecting a mammal in need of stimulation of release of a CXC chemokine;   administering to the mammal a polypeptide, wherein the polypeptide comprises a sequence having at least 95% sequence identity with residues 20 to 105 of SEQ ID NO:5; and   measuring the release of a CXC chemokine in a biological sample from said mammal, wherein said polypeptide stimulates the release of a CXC chemokine in said mammal.   
     
     
         4 . The method of  claim 3 , wherein the polypeptide comprises a sequence having at least 96% sequence identity with residues 20 to 105 of SEQ ID NO:5. 
     
     
         5 . The method of  claim 3 , wherein the polypeptide comprises a sequence having at least 97% sequence identity with residues 20 to 105 of SEQ ID NO:5. 
     
     
         6 . The method of  claim 3 , wherein the polypeptide comprises a sequence having at least 98% sequence identity with residues 20 to 105 of SEQ ID NO:5. 
     
     
         7 . The method of  claim 3 , wherein the polypeptide comprises a sequence having at least 99% sequence identity with residues 20 to 105 of SEQ ID NO:5. 
     
     
         8 . A method of stimulating neutrophil infiltration in a mammal in need thereof, comprising:
 selecting a mammal in need of stimulation of neutrophil infiltration;   administering to the mammal a polypeptide, wherein the polypeptide comprises a sequence having at least 95% sequence identity with residues 20 to 105 of SEQ ID NO:5; and   measuring the infiltration of neutrophils in a biological sample from said mammal, wherein said polypeptide stimulates neutrophil infiltration in said mammal.   
     
     
         9 . The method of  claim 8 , wherein the polypeptide comprises a sequence having at least 96% sequence identity with residues 20 to 105 of SEQ ID NO:5. 
     
     
         10 . The method of  claim 8 , wherein the polypeptide comprises a sequence having at least 97% sequence identity with residues 20 to 105 of SEQ ID NO:5. 
     
     
         11 . The method of  claim 8 , wherein the polypeptide comprises a sequence having at least 98% sequence identity with residues 20 to 105 of SEQ ID NO:5. 
     
     
         12 . The method of  claim 8 , wherein the polypeptide comprises a sequence having at least 99% sequence identity with residues 20 to 105 of SEQ ID NO:5. 
     
     
         13 . The method of  claim 1 , wherein said CXC chemokine is growth-related oncogene α (GROα). 
     
     
         14 . The method of  claim 1 , wherein said CXC chemokine is macrophage inflammatory protein (MIP)-2. 
     
     
         15 . The method of  claim 3 , wherein said CXC chemokine is growth-related oncogene α (GROα). 
     
     
         16 . The method of  claim 3 , wherein said CXC chemokine is macrophage inflammatory protein (MIP)-2. 
     
     
         17 . The method of  claim 1 , wherein said CXC chemokine is cytokine-induced neutrophil chemoattractant (CINC)-1. 
     
     
         18 . The method of  claim 1 , wherein said CXC chemokine is keratinocyte chemoattractant (KC). 
     
     
         19 . The method of  claim 3 , wherein said CXC chemokine is cytokine-induced neutrophil chemoattractant (CINC)-1. 
     
     
         20 . The method of  claim 3 , wherein said CXC chemokine is keratinocyte chemoattractant (KC).